Cutaneous vasculitis in children: A nationwide epidemiological study in Spain [version 1; referees: 2 approved]

Leyre Riancho-Zarrabeitia, Ana Santurtún

1 Department of Rheumatology, Sierrallana Hospital, Torrelavega, 39300, Spain
2 Department of Physiology and Pharmacology, Legal Medicine Unit, University of Cantabria, Santander, 39011, Spain

Abstract

Background: Cutaneous vasculitis (CV) are a complex group of conditions in children, of which IgA vasculitis (IgAV) is the most common. The objectives of the current study are to describe the incidence of CV in Spain and to analyze the temporal trend in the last 11 years, as well as it seasonal distribution.

Methods: Hospital discharges of patients aged 0-18 years with a diagnosis consistent with CV in Spain from 2005 to 2015 were collected from the Spanish National Institute of Statistics (INE) databases.

Results: A total of 7304 patients from January 2005 to December 2015 were included; 6991 patients (95%) had a diagnosis of IgAV. The yearly incidence in the whole group was 7.7 per 100,000. Mean age at diagnoses was 6±3 years and 52% were male. The highest rate of admissions was found in the 5-9 year-old group, followed by those with 0-4 years of age (15.7 and 9.0 admissions per 100,000, respectively). Admissions due to CV followed an annual cyclic pattern, with the highest number of daily admissions during fall and winter months and the lowest number in summer months. There was an overall downwards trend of the number of hospital admissions during the period of study, in both males and females (p=0.01).

Conclusions: We have estimated an incidence of a 7.7 cases per 100,000 CV in children in Spain. CV-related hospitalization rates have a marked seasonal pattern, with a peak in fall and winter and a nadir in summer months. Children between 5 and 9 years of age are most frequently affected. There is a decreasing trend in CV-related hospitalization, the causes of which should be further assessed.

Keywords

Cutaneous vasculitis, IgA vasculitis, Children
Corresponding author: Leyre Riancho-Zarrabeitia (eriancho@gmail.com)

Author roles: Riancho-Zarrabeitia L: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Santurtün A: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Riancho-Zarrabeitia L and Santurtün A. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Riancho-Zarrabeitia L and Santurtün A. Cutaneous vasculitis in children: A nationwide epidemiological study in Spain [version 1; referees: 2 approved] F1000Research 2017, 6:1527 (doi: 10.12688/f1000research.12372.1)

First published: 21 Aug 2017, 6:1527 (doi: 10.12688/f1000research.12372.1)
**Introduction**

Cutaneous vasculitis (CV) are a complex group of conditions in children. The most common are IgA vasculitis (IgAV) (formerly known as Schonlein-Henoch purpura, (SHP)), which represents more than half of the cases, followed by cutaneous small-vessel vasculitis (formerly known as hypersensitivity vasculitis). Other disorders, such as urticarial vasculitis or ANCA associated vasculitis are poorly represented in children. The global incidence is not known, while incidence of IgAV in children range from 3–26.7 per 100,000. Symptoms vary from a cutaneous-limited disorder to a systemic disease, and the etiology is not fully understood. However in many cases, particularly in IgAV, an external trigger is frequently suspected; IgAV in children has been frequently associated with a preceding upper respiratory infection, but no specific pathogen has been identified. It has also been linked to antibiotics and other medications. The reported seasonal pattern, with a fall-winter incidence peak, is consistent with the hypothesis of an infectious trigger.

The aims of our study are to describe the incidence of CV in Spain and to analyze the temporal trend of CV in the last 11 years, as well as it seasonal distribution.

**Methods**

Hospital discharges with a diagnosis consistent with CV (International Classification of Diseases ICD-9 codes hypersensitivity angiitis (446.2) and allergic purpura, including SHP (287.0)) in Spain from January 2005 to December 2015 were collected from the Spanish National Institute of Statistics (INE) databases. We calculated the overall average incidence of admission per 100,000 inhabitants during the 11 years in children (from 0 to 18 years). Moreover, we calculated the annual rate of admission in children, and for the temporary trend calculations, a Kendall’s tau correlation coefficient. Monthly admission rates were compared with Krustal-Wallis test. Statistical analysis were performed with R v2.3.

**Results**

A total of 7304 patients from 0 to 18 years of age were discharged from January 2005 to December 2015 with a diagnosis of CV. 6991 patients (95%) had a diagnosis of IgAV and 313 had hypersensitivity angiitis. The yearly incidence in the whole group was 7.7 per 100,000. Mean age at diagnosis was 6±3 years and 52% were male, with a male to female ratio of 1.02:1. The highest rate of admissions was found in the 5–9 year-old group, followed by those aged 0–4 years (15.7 and 9.0 admissions per 100,000, respectively) (Figure 1).

Admissions due to CV followed an annual cyclic pattern (Figure 2), with the highest number of daily admissions during fall and winter months and the lowest number in summer months. This pattern was consistent over the 11 years of study, with a 3-fold increase in the number of daily admissions in October compared with August (p<<0.001; Figure 3).

The annual analysis showed a downwards trend of the number of hospital admissions during the 11-year period of study, in both men and women (p=0.01; Figure 4).

---

*Figure 1. Incidence of cutaneous vasculitis across age groups between January 2005 and December 2015. The highest incidence occurred in children 5–9 years of age.*
Figure 2. Monthly incidence of cutaneous vasculitis during the period of study (January 2005–December 2015). A cyclic pattern was revealed, with a peak during fall and winter months and a nadir in summer.

Figure 3. Average (mean and standard deviation) monthly incidence of cutaneous vasculitis during the period of study (January 2005–December 2015). The combined analysis confirms the seasonal pattern throughout the period of study.
Discussion

This is the first population-based study of CV among children in Spain. We report the incidence rate of admissions of children with CV, defined as IgA V and hypersensitivity angiitis, over 11 years.

We estimate a yearly incidence of 7.7 cases per 100,000. Data on incidences rate on CV are scarce, while previous series on IgA V have reported incidences that range from 6.1 in the Dutch population\(^4\) to 20.4 in the United Kingdom\(^5\). Most published series report incidences between 10 and 20 cases per 100,000, with some discrepancies probably due to the heterogeneity of the criteria used and also by the source of identification of cases (those based exclusively in hospital discharge data fail to identify children not referred to the hospital). The incidence we report in Spanish children keeps in line with previous literature, being in the lower part of the range. Our estimates are based on hospitalized cases, which might somewhat underestimate true incidence. However, we feel our estimated incidence should be close to the true incidence, as most cases are attended to at a hospital, at least in western countries. This idea is supported by a US study reporting that only 10% of children with IgA V were reported exclusively by primary care physicians\(^6\) and by a UK study showing that only 3% of IgA V cases were reported by general practitioners\(^7\).

IgA V mainly affects children between 3 and 12 years of age\(^3\), with a mean age of 5–6 years in most paediatric series\(^6\–8\). A slightly male predominance has been reported, with a male to female ratio of up to 1.8:1\(^5\–7\), while others reported that cases were equally distributed\(^8\), or even a subtle female predominance\(^9\). In our case, we found a mean age of 6 years with no differences in sex distribution.

We found a remarkable seasonal variation in the frequency of CV. This is in line with other studies showing that IgA V has a seasonal distribution, with a peak during fall and winter and a nadir during summer months\(^3\,10\). This keeps in line with a commonly reported upper respiratory infection preceding the onset of the purpura, and a possible infectious trigger for the disease. Moreover, this increase during fall-winter time could also be related with atmospheric circulation patterns, as recently suggested for Kawasaki disease\(^11\).

Our annual analysis showed a downwards trend of the number of hospital admissions during the period of study. A similar trend has been reported previously. Okubo \textit{et al.}\(^6\) found a significant decreasing trend, with a total annual hospitalization rate of 2.45 per 100,000 children in 2003, falling to 1.89 per 100,000 children in 2012. This decrease could indicate a tendency to treat patients with IgA V in outpatient clinics, but also could reflect a real decrease in the incidence of the disease.

In summary, we have estimated an incidence of a 7.7 cases per 100,000 CV in children in Spain. CV-related hospitalization rates have a marked seasonal pattern, with a peak in fall and winter and a
nadir in summer months. Children between 5 to 9 years of age are most frequently affected. There is a decreasing trend in CV-related hospitalization, the cause of which should be further assessed.

**Data availability**

Data were downloaded freely from the Spanish National Institute of Statistics (INE) databases: http://www.ine.es/prodyser/microdatos.htm.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

---

**References**

1. Johnson EF, Wetter DA, Lehman JS, et al.: Leukocytoclastic vasculitis in children: clinical characteristics, subtypes, causes and direct immunofluorescence findings of 56 biopsy-confirmed cases. *J Eur Acad Dermatol Venereol*. 2017; 31(3): 544–549. [PubMed Abstract](#) [Publisher Full Text](#)

2. Ting TV: Diagnosis and management of cutaneous vasculitis in children. *Pediatr Clin North Am*. 2014; 61(2): 321–346. [PubMed Abstract](#) [Publisher Full Text](#)

3. Piram M, Mahr A: Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. *Curr Opin Rheumatol*. 2013; 25(2): 171–178. [PubMed Abstract](#) [Publisher Full Text](#)

4. Aalberse J, Dolman K, Ramnath G, et al.: Henoch Schönlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. *Ann Rheum Dis*. 2007; 66(12): 1648–1650. [PubMed Abstract](#) [Publisher Full Text](#) [Free Full Text](#)

5. Gardner-Medwin JM, Dolezalova P, Cummins C, et al.: Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. *Lancet*. 2002; 360(9341): 1197–1202. [PubMed Abstract](#) [Publisher Full Text](#) [Free Full Text](#)

6. Okubo Y, Nochioha K, Sakakibara H, et al.: Nationwide epidemiological survey of childhood IgA vasculitis associated hospitalization in the USA. *Clin Rheumatol*. 2016; 35(11): 2749–2756. [PubMed Abstract](#) [Publisher Full Text](#)

7. Trapani S, Micheli A, Grisola F, et al.: Henoch Schönlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. *Semn Arthritis Rheum*. 2006; 55(3): 143–153. [PubMed Abstract](#) [Publisher Full Text](#)

8. Piram M, Maldini C, Biscardi S, et al.: Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study. *Rheumatology (Oxford)*. 2017; 56(8): 1368–1366. [PubMed Abstract](#) [Publisher Full Text](#)

9. Garcia-Porrúa C, Calvittio MC, Llorca J, et al.: Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. *Semn Arthritis Rheum*. 2002; 32(3): 149–156. [PubMed Abstract](#) [Publisher Full Text](#)

10. Penny K, Fleming M, Kazmierczak O, et al.: An epidemiological study of Henoch-Schönlein purpura. *Paediatr Nurs*. 2010; 22(10): 30–35. [PubMed Abstract](#) [Publisher Full Text](#)

11. Rodó X, Curcoll R, Robinson M, et al.: Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. *Proc Natl Acad Sci U S A*. 2014; 111(22): 7952–7957. [PubMed Abstract](#) [Publisher Full Text](#) [Free Full Text](#)
Open Peer Review

Current Referee Status:  ✔  ✔

Version 1

Referee Report 20 July 2018
doi:10.5256/f1000research.13398.r35432

Robert Micheletti
Department of Dermatology and Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

The manuscript is an interesting epidemiologic study of the incidence of cutaneous vasculitis in children. In particular, the observation of seasonality of the condition, as well as the estimation of the overall incidence and the declining incidence over time, are informative.

I do have some questions / criticisms that could perhaps be addressed in the discussion / limitations to make this a stronger paper:

- One limitation is the diagnosis codes used (hypersensitivity angiitis and Henoch-Schonlein purpura). Are these the only codes? The best codes? It seems worth mentioning the limitations of identifying cases in this manner, since not all cases of interest may be identified. If you are not accurately including other types of cutaneous vasculitis with the "hypersensitivity angiitis" code, perhaps this is just a study of IgA vasculitis alone and should be described in that manner?
- The authors argue that their estimate of hospitalized patients is representative of the true incidence of disease based on studies that primary care and general practitioners only handle a subsegment of cases. The inference is that most patients, therefore, end up at the hospital. I don't find this argument particularly persuasive? What about outpatient dermatology? Rheumatology? It is rare for me to manage IgA vasculitis in the hospital, whereas I have many outpatients with the disease. This limitation should be acknowledged (as the authors do), but probably I would eliminate the arguments related to most patients being hospitalized, etc.
- Additionally, the authors may wish to comment on the changing definition / criteria for IgA vasculitis. Since the Chapel Hill Consensus Conference nomenclature were revised in 2012 (in the middle of the years analyzed in this study), it is worth considering whether case definition affected frequency of diagnosis. Historically, children with palpable purpura were just called Henoch-Schonlein purpura without much effort to determine the presence of IgA, etc. It's possible in recent years some of these patients were classified as having other diagnoses.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 19 September 2017
doi:10.5256/f1000research.13398.r25207

Javier del Pino-Montes
Rheumatology Department, IBSAL, Salamanca University Hospital, Salamanca, Spain

This is an interesting study about the epidemiological data of cutaneous vasculitis in children in Spain. There is little information on this topic. It is common to find data from hospitals or registries but the value of this paper is that the data comes from all over Spain. It would be interesting to know if there are geographical differences,

Minor revision:

In the results section and Figure 4, children are analyzed by gender as men and women. Being a pediatric population, it is more consistent to use males and females

I recommend to accept the paper after minor revisions

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.